19 results on '"Price, Karen"'
Search Results
2. Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19.
- Author
-
Chew, Kara W, Chew, Kara W, Moser, Carlee, Daar, Eric S, Wohl, David A, Li, Jonathan Z, Coombs, Robert W, Ritz, Justin, Giganti, Mark, Javan, Arzhang Cyrus, Li, Yijia, Choudhary, Manish C, Deo, Rinki, Malvestutto, Carlos, Klekotka, Paul, Price, Karen, Nirula, Ajay, Fischer, William, Bala, Veenu, Ribeiro, Ruy M, Perelson, Alan S, Fletcher, Courtney V, Eron, Joseph J, Currier, Judith S, ACTIV-2/A5401 Study Team, Hughes, Michael D, Smith, Davey M, Chew, Kara W, Chew, Kara W, Moser, Carlee, Daar, Eric S, Wohl, David A, Li, Jonathan Z, Coombs, Robert W, Ritz, Justin, Giganti, Mark, Javan, Arzhang Cyrus, Li, Yijia, Choudhary, Manish C, Deo, Rinki, Malvestutto, Carlos, Klekotka, Paul, Price, Karen, Nirula, Ajay, Fischer, William, Bala, Veenu, Ribeiro, Ruy M, Perelson, Alan S, Fletcher, Courtney V, Eron, Joseph J, Currier, Judith S, ACTIV-2/A5401 Study Team, Hughes, Michael D, and Smith, Davey M
- Abstract
Anti-SARS-CoV-2 monoclonal antibodies are mainstay COVID-19 therapeutics. Safety, antiviral, and clinical efficacy of bamlanivimab were evaluated in the randomized controlled trial ACTIV-2/A5401. Non-hospitalized adults were randomized 1:1 within 10 days of COVID-19 symptoms to bamlanivimab or blinded-placebo in two dose-cohorts (7000 mg, n = 94; 700 mg, n = 223). No differences in bamlanivimab vs placebo were observed in the primary outcomes: proportion with undetectable nasopharyngeal SARS-CoV-2 RNA at days 3, 7, 14, 21, and 28 (risk ratio = 0.82-1.05 for 7000 mg [p(overall) = 0.88] and 0.81-1.21 for 700 mg [p(overall) = 0.49]), time to symptom improvement (median 21 vs 18.5 days [p = 0.97], 7000 mg; 24 vs 20.5 days [p = 0.08], 700 mg), or grade 3+ adverse events. However, bamlanivimab was associated with lower day 3 nasopharyngeal viral levels and faster reductions in inflammatory markers and viral decay by modeling. This study provides evidence of faster reductions in nasopharyngeal SARS-CoV-2 RNA levels but not shorter symptom durations in non-hospitalized adults with early variants of SARS-CoV-2.
- Published
- 2022
3. Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development
- Author
-
Regev, Arie, Avigan, Mark I, Kiazand, Alexandre, Vierling, John M, Lewis, James H, Omokaro, Stephanie O, Di Bisceglie, Adrian M, Fontana, Robert J, Bonkovsky, Herbert L, Freston, James W, Uetrecht, Jack P, Miller, Ethan D, Pehlivanov, Nonko D, Haque, Syed Asif, Harrison, Melanie J, Kullak-Ublick, Gerd A; https://orcid.org/0000-0002-0757-4408, Li, Hewei, Patel, Niti N, Patwardhan, Meenal, Price, Karen D, Watkins, Paul B, Chalasani, Naga P, Regev, Arie, Avigan, Mark I, Kiazand, Alexandre, Vierling, John M, Lewis, James H, Omokaro, Stephanie O, Di Bisceglie, Adrian M, Fontana, Robert J, Bonkovsky, Herbert L, Freston, James W, Uetrecht, Jack P, Miller, Ethan D, Pehlivanov, Nonko D, Haque, Syed Asif, Harrison, Melanie J, Kullak-Ublick, Gerd A; https://orcid.org/0000-0002-0757-4408, Li, Hewei, Patel, Niti N, Patwardhan, Meenal, Price, Karen D, Watkins, Paul B, and Chalasani, Naga P
- Abstract
Immune checkpoint inhibitors (ICIs) have shown significant efficacy in patients with various malignancies, however, they are associated with a wide range of immune-related toxicities affecting many organs, including the liver. Immune-mediated liver injury caused by checkpoint inhibitors (ILICI) is a distinctive form of drug induced liver injury (DILI), that differs from most DILI types in presumed underlying mechanism, incidence, and response to therapeutic interventions. Despite increased awareness of ILICI and other immune-related adverse effects of ICIs reflected by recent guidelines for their management in post marketing clinical practice, there is lack of uniform best practices to address ILICI risk during drug development. As efforts to develop safer and more effective ICIs for additional indications grow, and as combination therapies including ICIs are increasingly investigated, there is a growing need for consistent practices for ILICI in drug development. This publication summarizes current best practices to optimize the monitoring, diagnosis, assessment, and management of suspected ILICI in clinical trials using ICI as a single agent and in combination with other ICIs or other oncological agents. It is one of several publications developed by the IQ DILI Initiative in collaboration with DILI experts from academia and regulatory agencies. Recommended best practices are outlined pertaining to hepatic inclusion and exclusion criteria, monitoring of liver tests, ILICI detection, approach to a suspected ILICI signal, causality assessment, hepatic discontinuation rules and additional medical treatment.
- Published
- 2020
4. Glacier Lake 513, Peru: lessons for early warning service development
- Author
-
Huggel, Christian, Cochachin, Alejo, Drenkhan, Fabian; https://orcid.org/0000-0002-9443-9596, Fluixá-Sanmartín, Javier, Frey, Holger, García Hernández, Javier, Jurt, Christine, Muñoz, Randy, Price, Karen, Vicuña, Luis, Huggel, Christian, Cochachin, Alejo, Drenkhan, Fabian; https://orcid.org/0000-0002-9443-9596, Fluixá-Sanmartín, Javier, Frey, Holger, García Hernández, Javier, Jurt, Christine, Muñoz, Randy, Price, Karen, and Vicuña, Luis
- Published
- 2020
5. Limited Sustained Local Transmission of HIV-1 CRF01_AE in New South Wales, Australia
- Author
-
Di Giallonardo, Francesca, Pinto, Angie N; https://orcid.org/0000-0003-3583-9490, Keen, Phillip; https://orcid.org/0000-0002-2678-0645, Shaik, Ansari, Carrera, Alex, Salem, Hanan, Telfer, Barbara, Cooper, Craig, Price, Karen, Selvey, Christine, Holden, Joanne, Bachmann, Nadine, Lee, Frederick J, Dwyer, Dominic E, Duchêne, Sebastián, Holmes, Edward C; https://orcid.org/0000-0001-9596-3552, Grulich, Andrew E, Kelleher, Anthony D, Di Giallonardo, Francesca, Pinto, Angie N; https://orcid.org/0000-0003-3583-9490, Keen, Phillip; https://orcid.org/0000-0002-2678-0645, Shaik, Ansari, Carrera, Alex, Salem, Hanan, Telfer, Barbara, Cooper, Craig, Price, Karen, Selvey, Christine, Holden, Joanne, Bachmann, Nadine, Lee, Frederick J, Dwyer, Dominic E, Duchêne, Sebastián, Holmes, Edward C; https://orcid.org/0000-0001-9596-3552, Grulich, Andrew E, and Kelleher, Anthony D
- Abstract
Australia's response to the human immunodeficiency virus type 1 (HIV-1) pandemic led to effective control of HIV transmission and one of the world's lowest HIV incidence rates-0.14%. Although there has been a recent decline in new HIV diagnoses in New South Wales (NSW), the most populous state in Australia, there has been a concomitant increase with non-B subtype infections, particularly for the HIV-1 circulating recombinant form CRF01_AE. This aforementioned CRF01_AE sampled in NSW, were combined with those sampled globally to identify NSW-specific viral clades. The population growth of these clades was assessed in two-year period intervals from 2009 to 2017. Overall, 109 NSW-specific clades were identified, most comprising pairs of sequences; however, five large clades comprising ≥10 sequences were also found. Forty-four clades grew over time with one or two sequences added to each in different two-year periods. Importantly, while 10 of these clades have seemingly discontinued, the remaining 34 were still active in 2016/2017. Seven such clades each comprised ≥10 sequences, and are representative of individual sub-epidemics in NSW. Thus, although the majority of new CRF01_AE infections were associated with small clades that rarely establish ongoing chains of local transmission, individual sub-epidemics are present and should be closely monitored.
- Published
- 2019
6. Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial
- Author
-
Phillips, Kelly-Anne, Aldridge, Julie, Ribi, Karin, Sun, Zhuoxin, Thompson, Alastair, Harvey, Vernon, Thürlimann, Beat, Cardoso, Fatima, Pagani, Olivia, Coates, Alan, Goldhirsch, Aron, Price, Karen, Gelber, Richard, Bernhard, Jürg, Phillips, Kelly-Anne, Aldridge, Julie, Ribi, Karin, Sun, Zhuoxin, Thompson, Alastair, Harvey, Vernon, Thürlimann, Beat, Cardoso, Fatima, Pagani, Olivia, Coates, Alan, Goldhirsch, Aron, Price, Karen, Gelber, Richard, and Bernhard, Jürg
- Abstract
Endocrine therapy for breast cancer may affect cognition. The purpose of this study was to examine whether cognitive function improves after cessation of adjuvant endocrine therapy. Change in cognitive function was assessed in 100 postmenopausal breast cancer patients in the BIG 1-98 trial, who were randomized to receive 5years of adjuvant tamoxifen or letrozole alone or in sequence. Cognitive function was evaluated by computerized tests during the fifth year of trial treatment (Y5) and 1year after treatment completion (Y6). Cognitive test scores were standardized according to age-specific norms and the change assessed using the Wilcoxon signed-rank test. There was significant improvement in the composite cognitive function score from Y5 to Y6 (median of change=0.22, effect size=0.53, P<0.0001). This improvement was consistent in women taking either tamoxifen or letrozole at Y5 (P=0.0006 and P=0.0002, respectively). For postmenopausal patients who received either adjuvant letrozole or tamoxifen alone or in sequence, cognitive function improved after cessation of treatment
- Published
- 2018
7. How doctors conceptualise P values: a mixed methods study
- Author
-
Tam, Chun Wah Michael, Khan, Abeer Hasan, Knight, Andrew, Rhee, Joel J, Price, Karen, McLean, Katrina, Tam, Chun Wah Michael, Khan, Abeer Hasan, Knight, Andrew, Rhee, Joel J, Price, Karen, and McLean, Katrina
- Abstract
Background and objectives: Researchers and clinicians have been criticised for frequently misinterpreting and misusing P values. This study sought to understand how general practitioners (GPs) in Australia and New Zealand conceptualise P values presented in the manner typically encountered in a medical publication. Methods: This mixed-methods study used quantitative and qualitative questions embedded in an online questionnaire and delivered through an Australian and New Zealand GP-specific Facebook group in 2017. It included questions that elaborated on the participant's conceptualisation of 'P = 0.05' within a scenario and tested their P value interpretation ability and confidence. Results: There were 247 participants who completed the questionnaire. Participant conceptualisations of P values were described using six thematic categories. The most common (and erroneous) conceptualisation was that P values numerically indicated a 'real-world probability'. No demographic factor, including research experience, seemed associated with better interpretation ability. A confidence-ability gap was detected. Discussion: P value misunderstanding is pervasive and might be influenced by a few central misconceptions. Statistics education for clinicians should explicitly address the most common misconceptions.
- Published
- 2018
8. Vangl2, a planar cell polarity molecule, is implicated in irreversible and reversible kidney glomerular injury
- Author
-
Papakrivopoulou, Eugenia, Vasilopoulou, Elisavet, Lindenmeyer, Maja T, Pacheco, Sabrina, Brzóska, Hortensja ?, Price, Karen L, Kolatsi-Joannou, Maria, White, Kathryn E, Henderson, Deborah J, Dean, Charlotte H, Cohen, Clemens D, Salama, Alan D, Woolf, Adrian S, Long, David A, Papakrivopoulou, Eugenia, Vasilopoulou, Elisavet, Lindenmeyer, Maja T, Pacheco, Sabrina, Brzóska, Hortensja ?, Price, Karen L, Kolatsi-Joannou, Maria, White, Kathryn E, Henderson, Deborah J, Dean, Charlotte H, Cohen, Clemens D, Salama, Alan D, Woolf, Adrian S, and Long, David A
- Abstract
Planar cell polarity (PCP) pathways control the orientation and alignment of epithelial cells within tissues. Van Gogh-like 2 (Vangl2) is a key PCP protein that is required for normal differentiation of kidney glomeruli and tubules. Vangl2 has also been implicated in modifying the course of acquired glomerular disease and here we further explored how Vangl2 impacts on glomerular pathobiology in this context. Targeted genetic deletion of Vangl2 in mouse glomerular epithelial podocytes enhanced the severity of not only irreversible accelerated nephrotoxic nephritis but also lipopolysaccharide-induced reversible glomerular damage. In each proteinuric model, genetic deletion of Vangl2 in podocytes was associated with an increased ratio of active-MMP9 to inactive MMP9, an enzyme involved in tissue remodelling. Additionally, by interrogating microarray data from two cohorts of renal patients, we report increased VANGL2 transcript levels in glomeruli of individuals with focal segmental glomerulosclerosis, suggesting that the molecule may also be involved in certain human glomerular diseases. These observations support the conclusion that Vangl2 modulates glomerular injury, at least in part by acting as a brake on MMP9, a potentially harmful endogenous enzyme.
- Published
- 2018
9. Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer
- Author
-
Viale, Giuseppe, Regan, Meredith M., Mastropasqua, Mauro G., Maffini, Fausto, Maiorano, Eugenio, Colleoni, Marco, Price, Karen N., Golouh, Rastko, Perin, Tiziana, Brown, R. W., Kovács, Anikó, Pillay, Komala, Öhlschlegel, Christian, Gusterson, Barry A., Castiglione-Gertsch, Monica, Gelber, Richard D., Goldhirsch, Aron, Coates, Alan S., Viale, Giuseppe, Regan, Meredith M., Mastropasqua, Mauro G., Maffini, Fausto, Maiorano, Eugenio, Colleoni, Marco, Price, Karen N., Golouh, Rastko, Perin, Tiziana, Brown, R. W., Kovács, Anikó, Pillay, Komala, Öhlschlegel, Christian, Gusterson, Barry A., Castiglione-Gertsch, Monica, Gelber, Richard D., Goldhirsch, Aron, and Coates, Alan S.
- Abstract
Several small studies have reported that having a high percentage of breast tumor cells that express the proliferation antigen Ki-67 (ie, a high Ki-67 labeling index) predicts better response to neoadjuvant chemotherapy. However, the predictive value of a high Ki-67 labeling index for response to adjuvant chemotherapy is unclear. To investigate whether Ki-67 labeling index predicts response to adjuvant chemoendocrine therapy, we assessed Ki-67 expression in tumor tissue from 1924 (70%) of 2732 patients who were enrolled in two randomized International Breast Cancer Study Group trials of adjuvant chemoendocrine therapy vs endocrine therapy alone for node-negative breast cancer. A high Ki-67 labeling index was associated with other factors that predict poor prognosis. Among the 1521 patients with endocrine-responsive tumors, a high Ki-67 labeling index was associated with worse disease-free survival but the Ki-67 labeling index did not predict the relative efficacy of chemoendocrine therapy compared with endocrine therapy alone. Thus, Ki-67 labeling index was an independent prognostic factor but was not predictive of better response to adjuvant chemotherapy in these studies
- Published
- 2017
10. CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- Author
-
Regan, Meredith M., Leyland-Jones, Brian, Bouzyk, Mark, Pagani, Olivia, Tang, Weining, Kammler, Roswitha, Dell'Orto, Patrizia, Biasi, Maria Olivia, Thürlimann, Beat, Lyng, Maria B., Ditzel, Henrik J., Neven, Patrick, Debled, Marc, Maibach, Rudolf, Price, Karen N., Gelber, Richard D., Coates, Alan S., Goldhirsch, Aron, Rae, James M., Viale, Giuseppe, Regan, Meredith M., Leyland-Jones, Brian, Bouzyk, Mark, Pagani, Olivia, Tang, Weining, Kammler, Roswitha, Dell'Orto, Patrizia, Biasi, Maria Olivia, Thürlimann, Beat, Lyng, Maria B., Ditzel, Henrik J., Neven, Patrick, Debled, Marc, Maibach, Rudolf, Price, Karen N., Gelber, Richard D., Coates, Alan S., Goldhirsch, Aron, Rae, James M., and Viale, Giuseppe
- Abstract
Background Adjuvant tamoxifen therapy is effective for postmenopausal women with endocrine-responsive breast cancer. Cytochrome P450 2D6 (CYP2D6) enzyme metabolizes tamoxifen to clinically active metabolites, and CYP2D6 polymorphisms may adversely affect tamoxifen efficacy. In this study, we investigated the clinical relevance of CYP2D6 polymorphisms. Methods We obtained tumor tissues and isolated DNA from 4861 of 8010 postmenopausal women with hormone receptor-positive breast cancer who enrolled in the randomized, phase III double-blind Breast International Group (BIG) 1-98 trial between March 1998 and May 2003 and received tamoxifen and/or letrozole treatment. Extracted DNA was used for genotyping nine CYP2D6 single-nucleotide polymorphisms using polymerase chain reaction-based methods. Genotype combinations were used to categorize CYP2D6 metabolism phenotypes as poor, intermediate, and extensive metabolizers (PM, IM, and EM, respectively; n = 4393 patients). Associations of CYP2D6 metabolism phenotypes with breast cancer-free interval (referred to as recurrence) and treatment-induced hot flushes according to randomized endocrine treatment and previous chemotherapy were assessed. Cox proportional hazards models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). All statistical tests were two-sided. Results No association between CYP2D6 metabolism phenotypes and breast cancer-free interval was observed among patients who received tamoxifen monotherapy without previous chemotherapy (P = .35). PM or IM phenotype had a non-statistically significantly reduced risk of breast cancer recurrence compared with EM phenotype (PM or IM vs EM, HR of recurrence = 0.86, 95% CI = 0.60 to 1.24). CYP2D6 metabolism phenotype was associated with tamoxifen-induced hot flushes (P = .020). Both PM and IM phenotypes had an increased risk of tamoxifen-induced hot flushes compared with EM phenotype (PM vs EM, HR of hot flushes = 1.24, 95% CI = 0.96 to 1.59; IM vs
- Published
- 2017
11. Managing glacier related risks disaster in the Chucchún catchment, Cordillera Blanca, Peru
- Author
-
Salzmann, Nadine, Huggel, Christian, Nussbaumer, Samuel U, Ziervogel, Gina, Salzmann, N ( Nadine ), Huggel, C ( Christian ), Nussbaumer, S U ( Samuel U ), Ziervogel, G ( Gina ), Muñoz, Randy, Gonzales, César, Price, Karen, Rosario, Ana, Frey, Holger, García, Javier, Cochachin, Alejo, Portocarrero, César, Mesa, Luis, Salzmann, Nadine, Huggel, Christian, Nussbaumer, Samuel U, Ziervogel, Gina, Salzmann, N ( Nadine ), Huggel, C ( Christian ), Nussbaumer, S U ( Samuel U ), Ziervogel, G ( Gina ), Muñoz, Randy, Gonzales, César, Price, Karen, Rosario, Ana, Frey, Holger, García, Javier, Cochachin, Alejo, Portocarrero, César, and Mesa, Luis
- Abstract
Glacial lakes hazards have been a constant factor in the population of the Cordillera Blanca due their potential to generate glacial lake outburst fl olds (GLOFs), which can be increased by the effects of climate change. In past decades, the UGRH (Glaciology and Water Resource Unit) successful implemented security infrastructure, however, events like the GLOF of April 11 in Carhuaz highlighted the need to implement new risk management strategies. In response, the Glaciares Project has been carried out to implement three strategies to reduce risks in the Chucchún catchment through: (1) Knowledge generation, (2) building technical and institutional capacities and, (3) the institutionalization of risk management. Strategies focused on strengthening the Municipality of Carhuaz, the Civil Defense Platform and its members, leading to an improvement of risk management and being based under Peruvian laws. As a result, both the authorities and the population have improved their resilience to respond to the occurrence of GLOF. This chapter will discuss and analyze the strategies and actions implemented under the Glaciares Project to build a model of glacier related risk management and climate change adaptation.
- Published
- 2016
12. Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer.
- Author
-
Ribi, K, Aldridge, J, Phillips, K-A, Thompson, A, Harvey, Vernon, Thürlimann, Beat, Cardoso, Fatima, Pagani, Olivia, Coates, Alan, Goldhirsch, Aron, Price, Karen N., Gelber, R D, Bernhard, Jürg, BIG 1-98 Collaborative and International Breast Cancer Study Groups, International Breast Cancer Study Group, Ribi, K, Aldridge, J, Phillips, K-A, Thompson, A, Harvey, Vernon, Thürlimann, Beat, Cardoso, Fatima, Pagani, Olivia, Coates, Alan, Goldhirsch, Aron, Price, Karen N., Gelber, R D, Bernhard, Jürg, BIG 1-98 Collaborative and International Breast Cancer Study Groups, and International Breast Cancer Study Group
- Abstract
In the BIG 1-98 trial objective cognitive function improved in postmenopausal women 1 year after cessation of adjuvant endocrine therapy for breast cancer. This report evaluates changes in subjective cognitive function (SCF)., Journal Article, Randomized Controlled Trial, Research Support, N.I.H. Extramural, Research Support, Non-U.S. Gov't, SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2012
13. Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial
- Author
-
Phillips, Kelly-Anne, Aldridge, Julie, Ribi, Karin, Sun, Zhuoxin, Thompson, Alastair, Harvey, Vernon, Thürlimann, Beat, Cardoso, Fatima, Pagani, Olivia, Coates, Alan, Goldhirsch, Aron, Price, Karen N., Gelber, Richard, Bernhard, Jürg, Phillips, Kelly-Anne, Aldridge, Julie, Ribi, Karin, Sun, Zhuoxin, Thompson, Alastair, Harvey, Vernon, Thürlimann, Beat, Cardoso, Fatima, Pagani, Olivia, Coates, Alan, Goldhirsch, Aron, Price, Karen N., Gelber, Richard, and Bernhard, Jürg
- Abstract
Endocrine therapy for breast cancer may affect cognition. The purpose of this study was to examine whether cognitive function improves after cessation of adjuvant endocrine therapy. Change in cognitive function was assessed in 100 postmenopausal breast cancer patients in the BIG 1-98 trial, who were randomized to receive 5 years of adjuvant tamoxifen or letrozole alone or in sequence. Cognitive function was evaluated by computerized tests during the fifth year of trial treatment (Y5) and 1 year after treatment completion (Y6). Cognitive test scores were standardized according to age-specific norms and the change assessed using the Wilcoxon signed-rank test. There was significant improvement in the composite cognitive function score from Y5 to Y6 (median of change = 0.22, effect size = 0.53, P < 0.0001). This improvement was consistent in women taking either tamoxifen or letrozole at Y5 (P = 0.0006 and P = 0.0002, respectively). For postmenopausal patients who received either adjuvant letrozole or tamoxifen alone or in sequence, cognitive function improved after cessation of treatment. © 2010 Springer Science+Business Media, LLC., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2011
14. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial
- Author
-
Phillips, Kelly-Anne, Ribi, Karin, Sun, Zhuoxin, Stephens, Alisa, Thompson, Alastair, Harvey, Vernon, Thürlimann, Beat, Cardoso, Fatima, Pagani, Olivia, Coates, Alan, Goldhirsch, Aron, Price, Karen N., Gelber, Richard, Bernhard, Jürg, Phillips, Kelly-Anne, Ribi, Karin, Sun, Zhuoxin, Stephens, Alisa, Thompson, Alastair, Harvey, Vernon, Thürlimann, Beat, Cardoso, Fatima, Pagani, Olivia, Coates, Alan, Goldhirsch, Aron, Price, Karen N., Gelber, Richard, and Bernhard, Jürg
- Abstract
Cognitive function in postmenopausal women receiving letrozole or tamoxifen as adjuvant endocrine treatment was compared during the fifth year of treatment in a substudy of the BIG 1-98 trial. In BIG 1-98 patients were randomized to receive adjuvant (A) 5-years tamoxifen, (B) 5-years letrozole, (C) 2-years tamoxifen followed by 3-years letrozole, or (D) 2-years letrozole followed by 3-years tamoxifen. The primary comparison was the difference in composite score for patients taking letrozole (B + C; N=65) vs. tamoxifen (A + D; N=55). The patients taking letrozole had better overall cognitive function than those taking tamoxifen (difference in mean composite z-scores=0.28, P=0.04, 95% CI: 0.02, 0.54, Cohen's D=0.40 indicating small to moderate effect). In this substudy, breast cancer patients taking adjuvant letrozole during the fifth year of treatment had better cognitive function than those taking tamoxifen, suggesting aromatase inhibitors do not adversely impact cognition compared with tamoxifen. © 2010 Elsevier Ltd., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2010
15. Annexin A8 Is Up-Regulated During Mouse Mammary Gland Involution and Predicts Poor Survival in Breast Cancer
- Author
-
Stein, Torsten, Price, Karen N., Morris, Joanna S., Heath, Victoria J., Ferrier, Roderick K., Bell, Alexandra K., Pringle, Marie-Anne, Villadsen, René, Petersen, Ole William, Sauter, Guido, Bryson, Gareth, Mallon, Elizabeth A., Gusterson, Barry A., Stein, Torsten, Price, Karen N., Morris, Joanna S., Heath, Victoria J., Ferrier, Roderick K., Bell, Alexandra K., Pringle, Marie-Anne, Villadsen, René, Petersen, Ole William, Sauter, Guido, Bryson, Gareth, Mallon, Elizabeth A., and Gusterson, Barry A.
- Published
- 2005
16. Re-evaluating Adjuvant Breast Cancer Trials: Assessing Hormone Receptor Status by Immunohistochemical Versus Extraction Assays
- Author
-
Regan, Meredith M., Viale, Giuseppe, Mastropasqua, Mauro G., Maiorano, Eugenio, Golouh, Rastko, Carbone, Antonino, Brown, Bob, Suurküla, Mart, Langman, Gerald, Mazzucchelli, Luca, Braye, Stephen, Grigolato, Piergiovanni, Gelber, Richard D., Castiglione-Gertsch, Monica, Price, Karen N., Coates, Alan S., Goldhirsch, Aron, Gusterson, Barry, Regan, Meredith M., Viale, Giuseppe, Mastropasqua, Mauro G., Maiorano, Eugenio, Golouh, Rastko, Carbone, Antonino, Brown, Bob, Suurküla, Mart, Langman, Gerald, Mazzucchelli, Luca, Braye, Stephen, Grigolato, Piergiovanni, Gelber, Richard D., Castiglione-Gertsch, Monica, Price, Karen N., Coates, Alan S., Goldhirsch, Aron, and Gusterson, Barry
- Abstract
Background: Tumor levels of steroid hormone receptors, a factor used to select adjuvant treatment for early-stage breast cancer, are currently determined with immunohistochemical assays. These assays have a discordance of 10%-30% with previously used extraction assays. We assessed the concordance and predictive value of hormone receptor status as determined by immunohistochemical and extraction assays on specimens from International Breast Cancer Study Group Trials VIII and IX. These trials predominantly used extraction assays and compared adjuvant chemoendocrine therapy with endocrine therapy alone among pre- and postmenopausal patients with lymph node-negative breast cancer. Trial conclusions were that combination therapy provided a benefit to pre- and postmenopausal patients with estrogen receptor (ER)-negative tumors but not to ER-positive postmenopausal patients. ER-positive premenopausal patients required further study. Methods: Tumor specimens from 571 premenopausal and 976 postmenopausal patients on which extraction assays had determined ER and progesterone receptor (PgR) levels before randomization from October 1, 1988, through October 1, 1999, were re-evaluated with an immunohistochemical assay in a central pathology laboratory. The endpoint was disease-free survival. Hazard ratios of recurrence or death for treatment comparisons were estimated with Cox proportional hazards regression models, and discriminatory ability was evaluated with the c index. All statistical tests were two-sided. Results: Concordance of hormone receptor status determined by both assays ranged from 74% (κ = 0.48) for PgR among postmenopausal patients to 88% (κ = 0.66) for ER in postmenopausal patients. Hazard ratio estimates were similar for the association between disease-free survival and ER status (among all patients) or PgR status (among postmenopausal patients) as determined by the two methods. However, among premenopausal patients treated with endocrine therapy alone, the disc
17. CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- Author
-
Regan, Meredith M., Leyland-Jones, Brian, Bouzyk, Mark, Pagani, Olivia, Tang, Weining, Kammler, Roswitha, Dell'Orto, Patrizia, Biasi, Maria Olivia, Thürlimann, Beat, Lyng, Maria B., Ditzel, Henrik J., Neven, Patrick, Debled, Marc, Maibach, Rudolf, Price, Karen N., Gelber, Richard D., Coates, Alan S., Goldhirsch, Aron, Rae, James M., Viale, Giuseppe, Regan, Meredith M., Leyland-Jones, Brian, Bouzyk, Mark, Pagani, Olivia, Tang, Weining, Kammler, Roswitha, Dell'Orto, Patrizia, Biasi, Maria Olivia, Thürlimann, Beat, Lyng, Maria B., Ditzel, Henrik J., Neven, Patrick, Debled, Marc, Maibach, Rudolf, Price, Karen N., Gelber, Richard D., Coates, Alan S., Goldhirsch, Aron, Rae, James M., and Viale, Giuseppe
- Abstract
Background Adjuvant tamoxifen therapy is effective for postmenopausal women with endocrine-responsive breast cancer. Cytochrome P450 2D6 (CYP2D6) enzyme metabolizes tamoxifen to clinically active metabolites, and CYP2D6 polymorphisms may adversely affect tamoxifen efficacy. In this study, we investigated the clinical relevance of CYP2D6 polymorphisms. Methods We obtained tumor tissues and isolated DNA from 4861 of 8010 postmenopausal women with hormone receptor-positive breast cancer who enrolled in the randomized, phase III double-blind Breast International Group (BIG) 1-98 trial between March 1998 and May 2003 and received tamoxifen and/or letrozole treatment. Extracted DNA was used for genotyping nine CYP2D6 single-nucleotide polymorphisms using polymerase chain reaction-based methods. Genotype combinations were used to categorize CYP2D6 metabolism phenotypes as poor, intermediate, and extensive metabolizers (PM, IM, and EM, respectively; n = 4393 patients). Associations of CYP2D6 metabolism phenotypes with breast cancer-free interval (referred to as recurrence) and treatment-induced hot flushes according to randomized endocrine treatment and previous chemotherapy were assessed. Cox proportional hazards models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). All statistical tests were two-sided. Results No association between CYP2D6 metabolism phenotypes and breast cancer-free interval was observed among patients who received tamoxifen monotherapy without previous chemotherapy (P = .35). PM or IM phenotype had a non-statistically significantly reduced risk of breast cancer recurrence compared with EM phenotype (PM or IM vs EM, HR of recurrence = 0.86, 95% CI = 0.60 to 1.24). CYP2D6 metabolism phenotype was associated with tamoxifen-induced hot flushes (P = .020). Both PM and IM phenotypes had an increased risk of tamoxifen-induced hot flushes compared with EM phenotype (PM vs EM, HR of hot flushes = 1.24, 95% CI = 0.96 to 1.59; IM vs
18. Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer
- Author
-
Viale, Giuseppe, Regan, Meredith M., Mastropasqua, Mauro G., Maffini, Fausto, Maiorano, Eugenio, Colleoni, Marco, Price, Karen N., Golouh, Rastko, Perin, Tiziana, Brown, R. W., Kovács, Anikó, Pillay, Komala, Öhlschlegel, Christian, Gusterson, Barry A., Castiglione-Gertsch, Monica, Gelber, Richard D., Goldhirsch, Aron, Coates, Alan S., Viale, Giuseppe, Regan, Meredith M., Mastropasqua, Mauro G., Maffini, Fausto, Maiorano, Eugenio, Colleoni, Marco, Price, Karen N., Golouh, Rastko, Perin, Tiziana, Brown, R. W., Kovács, Anikó, Pillay, Komala, Öhlschlegel, Christian, Gusterson, Barry A., Castiglione-Gertsch, Monica, Gelber, Richard D., Goldhirsch, Aron, and Coates, Alan S.
- Abstract
Several small studies have reported that having a high percentage of breast tumor cells that express the proliferation antigen Ki-67 (ie, a high Ki-67 labeling index) predicts better response to neoadjuvant chemotherapy. However, the predictive value of a high Ki-67 labeling index for response to adjuvant chemotherapy is unclear. To investigate whether Ki-67 labeling index predicts response to adjuvant chemoendocrine therapy, we assessed Ki-67 expression in tumor tissue from 1924 (70%) of 2732 patients who were enrolled in two randomized International Breast Cancer Study Group trials of adjuvant chemoendocrine therapy vs endocrine therapy alone for node-negative breast cancer. A high Ki-67 labeling index was associated with other factors that predict poor prognosis. Among the 1521 patients with endocrine-responsive tumors, a high Ki-67 labeling index was associated with worse disease-free survival but the Ki-67 labeling index did not predict the relative efficacy of chemoendocrine therapy compared with endocrine therapy alone. Thus, Ki-67 labeling index was an independent prognostic factor but was not predictive of better response to adjuvant chemotherapy in these studies
19. Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial
- Author
-
Phillips, Kelly-Anne, Aldridge, Julie, Ribi, Karin, Sun, Zhuoxin, Thompson, Alastair, Harvey, Vernon, Thürlimann, Beat, Cardoso, Fatima, Pagani, Olivia, Coates, Alan, Goldhirsch, Aron, Price, Karen, Gelber, Richard, Bernhard, Jürg, Phillips, Kelly-Anne, Aldridge, Julie, Ribi, Karin, Sun, Zhuoxin, Thompson, Alastair, Harvey, Vernon, Thürlimann, Beat, Cardoso, Fatima, Pagani, Olivia, Coates, Alan, Goldhirsch, Aron, Price, Karen, Gelber, Richard, and Bernhard, Jürg
- Abstract
Endocrine therapy for breast cancer may affect cognition. The purpose of this study was to examine whether cognitive function improves after cessation of adjuvant endocrine therapy. Change in cognitive function was assessed in 100 postmenopausal breast cancer patients in the BIG 1-98 trial, who were randomized to receive 5years of adjuvant tamoxifen or letrozole alone or in sequence. Cognitive function was evaluated by computerized tests during the fifth year of trial treatment (Y5) and 1year after treatment completion (Y6). Cognitive test scores were standardized according to age-specific norms and the change assessed using the Wilcoxon signed-rank test. There was significant improvement in the composite cognitive function score from Y5 to Y6 (median of change=0.22, effect size=0.53, P<0.0001). This improvement was consistent in women taking either tamoxifen or letrozole at Y5 (P=0.0006 and P=0.0002, respectively). For postmenopausal patients who received either adjuvant letrozole or tamoxifen alone or in sequence, cognitive function improved after cessation of treatment
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.